ProCE Banner Activity

Treatment Considerations for Stenotrophomonas maltophilia Infections

Clinical Thought

Stenotrophomonas maltophilia has been increasingly implicated in healthcare-acquired infections and intrinsically resistant to commonly used broad-spectrum β-lactam agents (eg, piperacillin/tazobactam, cefepime, carbapenems). Read this case study to learn my approach to S. maltophilia infections, including considerations for combination therapy.

Released: February 22, 2023

Expiration: February 21, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Shionogi Inc

Disclosure

Yohei Doi, MD, PhD: consultant/advisor/speaker: bioMérieux, Chugai, Fujifilm, Gilead Sciences, GlaxoSmithKline, Meiji Seika Pharma, Moderna, MSD, Shinogi; researcher: Entasis.